BMS Shares Jump on Reported AstraZeneca Tie-Up Worth About $400 Billion
TL;DR Summary
Bristol Myers Squibb stock rose about 4% premarket after a Financial Times report that BMS and AstraZeneca discussed a potential $400 billion merger, while AstraZeneca ADRs fell. The deal would be one of the largest in pharma history and comes as 2026 sees a wave of big M&A activity, though analysts warned mega-deals can slow R&D productivity and pipeline progress.
- Bristol Myers Squibb Stock Jumps on Report of $400 Billion Merger Talks With Big Rival Barron's
- AstraZeneca investors balk at $400 billion Bristol Myers tie-up reports Reuters
- Struggling to make sense of AstraZeneca-BMS Financial Times
- Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea Fierce Pharma
- AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports CNBC
Reading Insights
Total Reads
1
Unique Readers
3
Time Saved
5 min
vs 6 min read
Condensed
94%
1,053 → 60 words
Want the full story? Read the original article
Read on Barron's